Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Summary not available.
Summary not available.
Lineage Cell Therapeutics (LCTX) presented positive results from their Phase 1/2a clinical study of OpRegen at the 2023 ARVO Annual Meeting. The study focused on patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Key findings include:
- 7.6 letter gain in visual acuity observed in Cohort 4 over 12 months.
- Long-term vision preservation noted up to 4 years in treated eyes.
- Improved retinal structures correlated with the extent of OpRegen bleb coverage.
CEO Brian Culley expressed optimism about ongoing collaborations with Genentech and Roche. The ongoing Phase 2a study has started enrolling patients, highlighting the potential of OpRegen to address unmet medical needs in this debilitating condition.
Lineage Cell Therapeutics announced that CEO Brian M. Culley will present at the 2023 American Association of Pharmaceutical Scientists National Biotechnology Conference on April 25, 2023, at 10:00 am ET. His presentation is part of the “Evolution of Cellular Therapy Symposium”, which features discussions on advancements in cellular therapies. The conference runs from April 23-26, 2023, at the Philadelphia Marriott Downtown Hotel. Lineage specializes in allogeneic cell therapies and operates on a robust cell therapy platform, with multiple product candidates in development, including therapies for age-related macular degeneration and acute spinal cord injuries.
For more details, visit www.lineagecell.com.
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation will host the 1st Annual Spinal Cord Injury Investor Symposium on June 29, 2023, in La Jolla, CA. This event aims to unify healthcare companies, policymakers, and investors to discuss innovations in spinal cord injury treatment. Confirmed speakers include experts from RUSH University Medical Center and the Reeve Foundation. Lineage's CEO emphasized the need for collaboration to improve recovery and mobility for spinal cord injury patients. The symposium will explore current treatment approaches and clinical trial participation.
Lineage Cell Therapeutics announced the presentation of Phase 1/2a clinical study results for RG6501 (OpRegen) at the 2023 Retinal Cell and Gene Therapy Innovation Summit scheduled for April 21, 2023, in New Orleans, LA. OpRegen is being developed to treat geographic atrophy due to age-related macular degeneration (AMD) under a collaboration with Roche and Genentech. This therapy targets a compelling market need, as geographic atrophy affects over 5 million people globally, representing a significant opportunity for Lineage. The clinical presentation will be delivered by Eyal Banin, M.D., Ph.D., focusing on the implications of OpRegen in retinal therapy.
Lineage Cell Therapeutics (LCTX) has announced its financial and operational results for the fourth quarter and full year ended December 31, 2022. The company reported total revenues of approximately $1.9 million for Q4, a net increase of $0.7 million from Q4 2021. The full year revenues reached $14.7 million, up $10.4 million year-over-year. Operating expenses decreased to $36.5 million from $52.1 million in 2021, reflecting a significant reduction in R&D costs. The net loss attributable to Lineage was $26.3 million for the year, down from $43.0 million in 2021. The company continues advancing its clinical programs, notably the Phase 2a study of OpRegen in partnership with Roche.
Lineage Cell Therapeutics (NYSE American: LCTX) has announced the upcoming presentation of results from a Phase 1/2a clinical study of RG6501 (OpRegen) at the 2023 ARVO Annual Meeting in New Orleans, LA, from April 23-27, 2023. The presentation titled 'Exploratory optical coherence tomography analysis in patients with geographic atrophy treated by OpRegen' will be delivered by Eyal Banin, M.D., Ph.D. on April 25, 2023. OpRegen is aimed at treating geographic atrophy secondary to age-related macular degeneration. The therapy is being developed in collaboration with Roche and Genentech and is currently in Phase 2a evaluation.
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) announced it will report its fourth quarter and full year 2022 financial results on March 9, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss these results and provide a business update. Lineage focuses on developing allogeneic cell therapies for unmet medical needs, with several product candidates at various stages of clinical development, targeting markets with billion-dollar opportunities. Their portfolio includes therapies for conditions like age-related macular degeneration and acute spinal cord injuries.
Lineage Cell Therapeutics (LCTX) announced an exclusive option and license agreement with Eterna Therapeutics to develop novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell (iPSC) lines. This collaboration aims to create differentiated cell transplant therapies for central nervous system (CNS) disorders. Eterna's expertise in mRNA-based gene editing will enhance Lineage's capabilities in cell therapy. The agreement allows Lineage to sublicense these gene-edited cell lines for various purposes in CNS-related diseases. Financial terms remain undisclosed.